Ankasa Regenerative Therapeutics Overview
- Founded
-
2014
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Later Stage VC
- (Cancelled)
- Investors
-
5
Ankasa Regenerative Therapeutics General Information
Description
Developer of protein-based stem cell activation therapies intended to improve tissue repair and regeneration. The company's therapies enhance the osteogenic properties of patient-derived stem cells used in reconstructive surgeries and provide safe and effective enhancement of bone formation, enabling clinicians to reduce the rate of revision surgeries and their attendant complications.
Contact Information
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Therapeutic Devices
Biotechnology
Primary Office
- 11099 North Torrey Pines Road
- Suite 290, La Jolla
- San Diego, CA 92037
- United States
+1 (858) 000-0000
Ankasa Regenerative Therapeutics Timeline
Ankasa Regenerative Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 01-Jan-2021 | Cancelled | Generating Revenue | |||
| 3. Later Stage VC | 13-Oct-2020 | 000 | 000.00 | 000.00 | Completed | Generating Revenue |
| 2. Grant | 01-Aug-2019 | $6.08M | $9.5M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 30-Jul-2015 | $9.5M | $9.5M | 000.00 | Completed | Generating Revenue |
Ankasa Regenerative Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.00 |
Ankasa Regenerative Therapeutics Patents
Ankasa Regenerative Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20200399588-A1 | Wnt compositions and methods of process from serum-free culturing conditions | Pending | 01-Aug-2017 | 0000000000 | |
| CA-3071638-A1 | Wnt compositions and methods of process from serum-free culturing conditions | Pending | 01-Aug-2017 | 000000000 | |
| AU-2018309026-A1 | Wnt compositions and methods of process from serum-free culturing conditions | Pending | 01-Aug-2017 | 000000000 | |
| GB-202001567-D0 | Wnt compositions and methods of process from serum-free culturing | Pending | 01-Aug-2017 | 000000000 | |
| GB-2581882-A | Wnt compositions and methods of process from serum-free culturing | Pending | 01-Aug-2017 | C12N5/0031 | 0 |
Ankasa Regenerative Therapeutics Executive Team (5)
Ankasa Regenerative Therapeutics Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| Andre Kobelt Ph.D | Self | Board Member | 000 0000 |
| David Lacey MD | Self | Co-Founder & Chairman of Scientific Advisory Board | 000 0000 |
| Kevin Kinsella | Avalon Ventures | Board Member | 000 0000 |
| Sanford Madigan Ph.D | Self | Co-Founder, Chief Executive Officer & Board Member | 000 0000 |
| Tighe Reardon | Self | Board Member | 000 0000 |
Ankasa Regenerative Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Ankasa Regenerative Therapeutics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| California Institute for Regenerative Medicine | Government | 000 0000 | 000000 0 | ||
| Avalon Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Correlation Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Heraeus Holding | Corporation | Minority | 000 0000 | 000000 0 | |
| Stanford University Venture Fund | Venture Capital | Minority | 000 0000 | 000000 0 |